A detailed history of Meag Munich Ergo, Kapitalanlagegesellschaft Mb H transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Meag Munich Ergo, Kapitalanlagegesellschaft Mb H holds 933,748 shares of GILD stock, worth $85.3 Million. This represents 2.53% of its overall portfolio holdings.

Number of Shares
933,748
Previous 964,066 3.14%
Holding current value
$85.3 Million
Previous $66.1 Million 18.33%
% of portfolio
2.53%
Previous 2.24%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

SELL
$66.59 - $83.99 $2.02 Million - $2.55 Million
-30,318 Reduced 3.14%
933,748 $78.3 Million
Q2 2024

Aug 01, 2024

BUY
$63.15 - $72.88 $5.5 Million - $6.35 Million
87,167 Added 9.94%
964,066 $66.1 Million
Q1 2024

Apr 18, 2024

SELL
$71.58 - $87.29 $578,795 - $705,826
-8,086 Reduced 0.91%
876,899 $64.2 Million
Q4 2023

Jan 19, 2024

BUY
$73.27 - $83.09 $19.4 Million - $22 Million
264,282 Added 42.58%
884,985 $71.7 Million
Q3 2023

Oct 25, 2023

BUY
$73.94 - $80.67 $8.57 Million - $9.35 Million
115,865 Added 22.95%
620,703 $46.5 Million
Q2 2023

Jul 14, 2023

BUY
$76.01 - $86.7 $36.8 Million - $42 Million
484,502 Added 2382.48%
504,838 $38.9 Million
Q1 2023

Apr 20, 2023

SELL
$77.31 - $88.08 $1 Million - $1.14 Million
-12,998 Reduced 38.99%
20,336 $1.69 Million
Q4 2022

Jan 19, 2023

BUY
$62.32 - $89.47 $1.16 Million - $1.66 Million
18,554 Added 125.53%
33,334 $2.86 Million
Q3 2022

Oct 18, 2022

SELL
$59.54 - $68.01 $208,390 - $238,035
-3,500 Reduced 19.15%
14,780 $912,000
Q2 2022

Jul 19, 2022

BUY
$57.72 - $65.01 $622,221 - $700,807
10,780 Added 143.73%
18,280 $1.13 Million
Q1 2022

Apr 13, 2022

BUY
$57.92 - $72.58 $191,136 - $239,514
3,300 Added 78.57%
7,500 $451,000
Q3 2021

Oct 13, 2021

SELL
$67.69 - $73.03 $2.35 Million - $2.53 Million
-34,693 Reduced 89.2%
4,200 $293,000
Q2 2021

Jul 16, 2021

SELL
$63.47 - $69.35 $1.11 Million - $1.22 Million
-17,547 Reduced 31.09%
38,893 $2.68 Million
Q1 2021

Apr 20, 2021

BUY
$60.0 - $68.46 $1.32 Million - $1.5 Million
21,970 Added 63.74%
56,440 $3.65 Million
Q4 2020

Jan 20, 2021

BUY
$56.65 - $64.55 $339,900 - $387,300
6,000 Added 21.07%
34,470 $1.95 Million
Q3 2020

Oct 20, 2020

BUY
$62.1 - $78.08 $477,300 - $600,122
7,686 Added 36.98%
28,470 $1.8 Million
Q2 2020

Jul 16, 2020

SELL
$72.34 - $84.0 $873,143 - $1.01 Million
-12,070 Reduced 36.74%
20,784 $1.6 Million
Q1 2020

Apr 23, 2020

SELL
$62.63 - $80.22 $3.81 Million - $4.87 Million
-60,766 Reduced 64.91%
32,854 $2.46 Million
Q4 2019

Jan 17, 2020

SELL
$61.62 - $67.78 $2.29 Million - $2.52 Million
-37,214 Reduced 28.44%
93,620 $6.08 Million
Q3 2019

Oct 29, 2019

BUY
$62.51 - $69.0 $3.74 Million - $4.13 Million
59,865 Added 84.35%
130,834 $8.2 Million
Q2 2019

Jul 17, 2019

BUY
$61.87 - $69.38 $1.33 Million - $1.49 Million
21,540 Added 43.58%
70,969 $4.77 Million
Q1 2019

Apr 29, 2019

SELL
$62.53 - $70.05 $3.09 Million - $3.47 Million
-49,481 Reduced 50.03%
49,429 $3.15 Million
Q4 2018

Jan 29, 2019

BUY
$60.54 - $79.0 $548,250 - $715,424
9,056 Added 10.08%
98,910 $6.24 Million
Q3 2018

Oct 23, 2018

BUY
$71.28 - $78.92 $1.21 Million - $1.34 Million
17,027 Added 23.38%
89,854 $6.84 Million
Q2 2018

Jul 17, 2018

SELL
$64.88 - $75.68 $2.32 Million - $2.71 Million
-35,751 Reduced 32.93%
72,827 $5.17 Million
Q1 2018

May 02, 2018

BUY
$72.84 - $88.8 $421,525 - $513,885
5,787 Added 5.63%
108,578 $8.09 Million
Q4 2017

Jan 26, 2018

SELL
$71.15 - $83.52 $18.6 Million - $21.8 Million
-260,952 Reduced 71.74%
102,791 $7.49 Million
Q3 2017

Nov 06, 2017

BUY
$72.11 - $85.47 $26.2 Million - $31.1 Million
363,743
363,743 $29.5 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $114B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Meag Munich Ergo, Kapitalanlagegesellschaft Mb H Portfolio

Follow Meag Munich Ergo, Kapitalanlagegesellschaft Mb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meag Munich Ergo, Kapitalanlagegesellschaft Mb H, based on Form 13F filings with the SEC.

News

Stay updated on Meag Munich Ergo, Kapitalanlagegesellschaft Mb H with notifications on news.